Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180636 | 0.79 | HDAC3 (0.57) | RORCGAAMAPTLMNAHTT | |
| SCHEMBL13333313 | 0.77 | HDAC8 (0.46) | MAPTLMNAHTTSMN1; SMN2PKM | |
| SCHEMBL21185073 | 0.77 | CHEK1 (0.46) | GAAMAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL5251341 | 0.76 | HDAC3 (0.59) | LMNAHTTHDAC3HDAC4HDAC1 | |
| SCHEMBL17927624 | 0.75 | HDAC3 (0.50) | RORCMAPTHTTSMN1; SMN2HDAC3 | |
| Hydrochloric Acid SCHEMBL27513833 | 0.74 | HDAC3 (0.58) | LMNAHTTHDAC3HDAC4HDAC1 | |
| SCHEMBL29536178 | 0.73 | RORC (0.44) | RORCGAAMAPTLMNAHTT | |
| SCHEMBL21856719 | 0.73 | RORC (0.44) | RORCGAAMAPTLMNAHTT | |
| SCHEMBL29771205 | 0.73 | GLS (0.52) | GAALMNAHTTSMN1; SMN2PKM | |
| SCHEMBL27256037 | 0.73 | GLS (0.52) | GAALMNAHTTSMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| CN-101759645-B | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC | 2014-06-25 | — | — | CN | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8017641-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997811-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | RORC 581/4885GAA 3147/4885MAPT 1859/4885 |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | MAPK1, MAPK3, MAP3K1 | RORC 284/4885GAA 1749/4885MAPT 329/4885 |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | RORC 581/4885GAA 3147/4885MAPT 1859/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | RORC 696/4885GAA 2590/4885MAPT 1512/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | RORC 979/4885GAA 2099/4885MAPT 3575/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | RORC 696/4885GAA 2590/4885MAPT 1512/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | RORC 979/4885GAA 2099/4885MAPT 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.